Maxudin (Pravastatin Sodium)

• Pravastatin Sodium is indicated for disorders of lipid metabolism and for cardiovascular risk reduction.
• Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol and total cholesterol levels.
• Primary prevention of cardiovascular disease: reduces the incidence of myocardial infarction and stroke in patients at risk.
• Secondary prevention of cardiovascular disease: helps prevent recurrent cardiovascular events in patients with established coronary artery disease.

• Pravastatin Sodium competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis. This inhibition decreases intracellular cholesterol, leading to up‑regulation of LDL receptors on hepatocyte surfaces, which enhances clearance of circulating LDL particles and lowers plasma cholesterol concentrations.

Adverse reactions may occur with pravastatin therapy and are categorized by frequency.

Common Side Effects

• Headache: mild to moderate intensity.
• Gastrointestinal discomfort: including nausea, abdominal pain, or constipation.
• Myalgia: muscle aches without weakness.
• Elevated liver enzymes: mild transaminase increases.
• Dizziness: occasional light‑headedness.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with potential renal impairment.
• Acute hepatitis: marked elevation of liver enzymes with jaundice.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Myopathy with weakness: significant loss of muscle strength.
• Thrombocytopenia: low platelet count.
• Renal failure: secondary to muscle breakdown products.

• Pravastatin should be used with attention to patient‑specific factors and monitoring requirements.
• Pregnancy: contraindicated; classified Category X due to fetal risk.
• Liver disease: avoid in active hepatic impairment; monitor liver function tests.
• Renal impairment: dose adjustment may be needed in severe renal dysfunction.
• Drug interactions: review concomitant medications for potential CYP interactions.
• Alcohol consumption: limit intake as it may increase liver toxicity.
• Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture and light.

Pravastatin may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase pravastatin plasma levels.
• Gemfibrozil: heightened risk of myopathy and rhabdomyolysis.
• High‑dose niacin: may exacerbate liver toxicity.

Moderate Interactions (Monitor Closely)

• Cyclosporine: modest increase in pravastatin concentrations.
• Anticoagulants (warfarin): may enhance anticoagulant effect.
• Digoxin: potential for increased serum levels.
• Antacids containing aluminum or magnesium: may reduce absorption.